Therapeutic Response

HER2-positive status confers therapeutic sensitivity to Trastuzumab in patients with Invasive Breast Carcinoma.

Statements

Source and description
Herceptin (trastuzumab) [product monograph]. HC. Health Canada approved trastuzumab for the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2, following surgery and after chemotherapy.
Herceptin (trastuzumab) [product monograph]. HC. Health Canada approved trastuzumab for metastatic breast cancer in patients whose tumors overexpress HER2.
Herceptin (trastuzumab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to trastuzumab for the treatment of patients with HER2-overexpressing breast cancer. The product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for herceptin.